Detail akcie Insulet online

Business Summary: Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Insulet Corp revenues increased 30% to $1.7B. Net income increased from $4.6M to $206.3M. Revenues reflect Omnipod System segment increase of 41% to $1.25B, International Omnipod segment increase of 13% to $410.1M, United States segment increase of 37% to $1.29B, All Other segment increase of 13% to $410.1M. Net income benefited from Interest Income increase from $9.8M to $28.6M (income).